A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

← catalyst calendar

NCT07654972 · readout ≤ 985 d

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Randomized · Double · Basic science

Enrollment

108estimated

Sites

Countries

Singapore, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-06-24

actual

When the study began enrolling

Primary completion

Apr 2029

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Apr 2029

estimated

The whole study's end, after follow-up

First posted

2026-06-17

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-16

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Obesity
Overweight

Interventions

Drug: LY4174794
Drug: LY4174794
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

measured Baseline through end of the Follow-up (Week 25)

Part B: Number of Participants with One or More TEAEs and SAEs Considered by the Investigator to be Related to Study Drug Administration

measured Baseline through end of the Follow-up (Week 39)

Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed